Cellcolabs is a biotech company on a mission to accelerate stem cell research and make future treatments accessible to everyone. They specialize in advanced cell therapy research and treatments, with a focus on industrial Good Manufacturing Practice (GMP) production of high-quality stem cells. By scaling up their operations, Cellcolabs aims to reduce the price and increase the availability of these advanced cell therapies.

Drawing on over 20 years of experience in stem cell research at Karolinska Institutet, Cellcolabs ensures exceptional quality in their cells, derived from bone marrow and approved for use in clinical trials. Currently, they offer both research-grade and GMP-grade versions, with plans to expand to provide adipose and umbilical cord versions in the future. Cellcolabs recognizes the limitless application opportunities of their mesenchymal stromal cells (MSC), which have regenerative, immunomodulatory, and anti-inflammatory effects.

These cells hold the potential to cure or prevent various chronic diseases, such as Type 1 diabetes, Parkinson's disease, stroke, and arthritis. Researchers and organizations interested in purchasing MSC for research or treatments can reach out to Cellcolabs. For those looking for treatment options, Cellcolabs sponsors and partners in clinical studies, offering updates on opportunities to join these studies.

While they do not provide treatments directly, they play a vital role in advancing advanced cell therapy. Located in Stockholm, Sweden, Cellcolabs' production plant ensures the highest quality standards. Additionally, they welcome talent and invite interested individuals to join their growing team.

To support their mission, Cellcolabs also encourages cell donation to be part of the life-changing journey of advanced cell therapy. Contact Cellcolabs at info@cellcolabs. com or connect with them on LinkedIn to learn more about their pioneering work in the field of cell therapy